Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 3Leukemia, Myeloid 2Targeted Therapy 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Blast Crisis 1

Interventions

fludarabine 2durvalumab 2Cyclophosphamide 2ruxolitinib 1repotrectinib 1ponatinib 1pembrolizumab 1gilteritinib 1fludarabine phosphate 1cemiplimab 1atezolizumab 1Whole-Body Irradiation 1Tacrolimus 1Peripheral Blood Stem Cell Transplantation 1Pemetrexed 1Patient Reported Outcome Measures 1Nivolumab 1Mycophenolic Acid 1Mesna 1Melphalan 1Immunotherapy 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Docetaxel 1Cytarabine 1Cisplatin 1CPI-0610 1Busulfan 1Bone Marrow Transplantation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × gilteritinib × 90 days × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡